ArticleNeurology2017
Predictive markers for early conversion of iRBD to neurodegenerative synucleinopathy diseases.
Article in Neurology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study.Brain : a journal of neurology · 2019Trial
- Clinical markers of disease progression in the prodromal to overt alpha-synucleinopathy continuum.Brain : a journal of neurology · 2026Article
- Higher glymphatic system activity is linked to longer prodromal stage in isolated REM sleep behavior disorder: a possible protective factor.NPJ Parkinson's disease · 2026Article
- Susceptibility and diffusion MRI biomarkers predict development of Parkinsonism in iRBD.NPJ Parkinson's disease · 2025Article
- Choroid plexus enlargement in patients with rapid eye movement sleep behavior disorder: relevance to glymphatic system dysfunction.Sleep and biological rhythms · 2025Article
- Advances in autonomic dysfunction research in Parkinson's disease.Frontiers in aging neuroscience · 2025Review
- Potential dopaminergic deficit in patients with geriatric psychiatric disorders as revealed by DAT-SPECT: a cross-sectional study.BMJ mental health · 2024Article
- Magnetic Resonance Imaging and Nuclear Imaging of Parkinsonian Disorders: Where do we go from here?Current neuropharmacology · 2024Review
- Opportunities and Pitfalls of REM Sleep Behavior Disorder and Olfactory Dysfunction as Early Markers in Parkinson's Disease.Journal of Parkinson's disease · 2024Review
- Static and dynamic brain morphological changes in isolated REM sleep behavior disorder compared to normal aging.Frontiers in neuroscience · 2024Article
- Dopaminergic damage pattern predicts phenoconversion time in isolated rapid eye movement sleep behavior disorder.European journal of nuclear medicine and molecular imaging · 2023Article
- Brain glucose metabolism and nigrostriatal degeneration in isolated rapid eye movement sleep behaviour disorder.Brain communications · 2023Article
- Dysautonomia and REM sleep behavior disorder contributions to progression of Parkinson's disease phenotypes.NPJ Parkinson's disease · 2022Article
- Predictors of RBD progression and conversion to synucleinopathies.Current neurology and neuroscience reports · 2022Review
- Characterizing mild cognitive impairment in prodromal Parkinson's disease: A community-based study in China.CNS neuroscience & therapeutics · 2022Article
- Sleep and Autonomic Manifestations in Parkinson's Disease Complicated With Probable Rapid Eye Movement Sleep Behavior Disorder.Frontiers in neuroscience · 2022Article
- Research progress on neuromolecular imaging of REM sleep behavior disorder.Frontiers in neurology · 2022Review
- Stratification Tools for Disease-Modifying Trials in Prodromal Synucleinopathy.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Research progress in rapid eye movement sleep behavior disorder.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2021Article
- Biomarkers of conversion to α-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder.The Lancet. Neurology · 2021Review
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the predictive value of clinical assessment and dopamine transporter (DAT) uptake for the early development of neurodegenerative synucleinopathy diseases from idiopathic REM sleep behavior disorder (iRBD) over 5 years in a Chinese population.
methodsForty-three patients with iRBD were administered clinical assessment tests, and 35 were examined by DAT-SPECT imaging during 2011. Cox proportional hazard and Kaplan-Meier analyses were used to evaluate the predictive value of the markers in a follow-up study over 5 years.
resultsEighteen patients (41.9%) developed neurodegenerative synucleinopathy diseases after a median of 4.1 years of prospective follow-up (median interval of 10.5 years from the estimated onset of iRBD symptoms). Patients with higher scores on the Nonmotor Symptom Questionnaire (hazard ratio [HR] 3.11, 95% confidence interval [CI] 1.15-8.40,
conclusionsOur findings elucidate the predictive value of autonomic dysfunction and DAT uptake in identifying patients with iRBD at a high risk of progressing into neurodegenerative synucleinopathy diseases and could form a basis for future disease-prevention trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.